Novartis

By Laura Lovett 03:10 pm July 7, 2020
Novartis and respiratory health company Propeller Health, a ResMed subsidiary, have teamed up to co-package the latter’s digital health platform with the pharma giant’s new asthma medication Enerzair Breezhaler.  This news come shortly after the product landed European Commission clearance. The co-packaged product will be launching in the EU during 2020. However, it is not yet available in the U....
By Dave Muoio 03:15 pm June 24, 2020
FDA begins sharing patient's cancer drug experiences. The FDA's Oncology Center of Excellence has kicked off the first step of new pilot program that will increase the availability of patient-reported outcome data from cancer clinical trials. Project Patient Voice, as it's called, will start with making the data from a single trial accessible online while the agency solicits public feedback, but...
By Dave Muoio 03:43 pm May 4, 2020
Following numerous reports of underperforming COVID-19 antibody tests, the FDA has raised the bar for these products in a revision to its emergency testing policy. As of today, commercial manufacturers that notify the agency of their intent to submit a test for Emergency Use Authorization are required to do so within 10 business days from the date of notification. Further, the FDA has recommended...
By Dave Muoio 03:12 pm April 20, 2020
International pharma giant Novartis announced this morning the acquisition of Amblyotech, a startup that combines 3D glasses and video game software to treat amblyopia, more commonly known as "lazy eye." The terms of the deal were not disclosed. Novartis also said that it will be developing new games and kicking off a proof-of-concept study alongside major French video game publisher Ubisoft and...
By Dave Muoio 05:01 pm December 13, 2019
It has been a tumultuous week in the realm of digital health partnerships. It started with word of Proteus Digital Health’s floundering business and failed investment round, which reports say was partially driven by cooling relations between the digital pill maker and its longtime patron Otsuka Pharmaceuticals. A few days later, Sanofi announced a company-wide strategy shift that found Onduo, its...

Credit: Popit

By Leontina Postelnicu 05:10 am November 27, 2019
Espoo, Finland-based Popit, maker of a smart pill tracker, has revealed this month that it is teaming up with Swiss pharma giant Novartis in an initiative aiming to improve patients' adherence to medication. The announcement follows the startup's work with Pfizer to support patients receiving treatment for rheumatoid arthritis. Last week, at Slush, MobiHealthNews sat down with Popit cofounder and...

Credit: Novartis

By Leontina Postelnicu 01:25 am November 22, 2019
Swiss pharma giant Novartis has announced this week two collaboration agreements with Finnish startups Popit and Precordior, unveiled at Slush, a startup event taking place in Helsinki. WHY IT MATTERS Launched in 2017, Espoo, Finland-based Popit has created a solution to improve patients’ engagement and adherence to medication. “We have a piece of hardware that we clip onto a medication blister,...
By Dave Muoio 03:12 pm November 20, 2019
Sanofi is merging its real-world data platform with New York startup Aetion’s similar evidence platform to augment its treatment development and deployment efforts, the companies announced today. Sanofi’s DARWIN platform will provide a substantial body of de-identified patient data, which the Aetion Evidence Platform will analyze those information for insights on drug effectiveness, safety and...
By Laura Lovett 11:49 am November 18, 2019
This morning Biofourmis, maker of an artificial intelligence-enabled monitoring and decision support platform, announced its plans to acquire Zürich, Switzerland-based wearable biosensor company Biovotion. The terms of the deal are not disclosed; however, we do know the deal is made up of a combination of cash and equity.  The acquisition will include Biovotion’s clinical grade-wearable...
By Dave Muoio 10:28 am October 16, 2019
Editor's Note: This story has been updated with additional quotes from Pear Therapeutics. The poster child of digital therapeutics-pharma collaborations is soon to be no more, as Novartis division Sandoz announced that it is handing sole responsibility for the commercialization of the reSET and reSET-O prescription digital therapeutics back to Pear Therapeutics. “Pear and Sandoz previously signed...